Related Experiment Video

Updated: Mar 24, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.7K

Trends in the development of MET inhibitors for hepatocellular carcinoma

Hitomi S Okuma1, Shunsuke Kondo1

  • 1Department of Experimental Therapeutics, National Cancer Center, Tokyo, Japan.

Future Oncology (London, England)
|March 18, 2016
PubMed

Insights

Hepatocellular carcinoma (HCC) treatments need improvement. The MET pathway is a promising new target for HCC therapies, with several drugs in development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally.
  • Current standard-of-care treatments like sorafenib offer limited benefits.
  • The MET pathway (encoded by HGFR) is implicated in HCC development and progression.

Purpose of the Study:

  • To review the role of MET in hepatocellular carcinoma.
  • To discuss emerging MET inhibitors as potential therapeutic agents for HCC.

Main Methods:

  • Literature review of scientific publications.
  • Analysis of clinical trial data for MET-targeted therapies.
  • Examination of the molecular mechanisms of MET activation in HCC.

Main Results:

  • MET is frequently activated in HCC through amplification, overexpression, or mutation.
  • Several drugs targeting the HGF/MET axis are under investigation in clinical trials.
  • MET inhibitors show potential as novel therapeutic strategies for HCC.

Conclusions:

  • Targeting the HGF/MET axis represents a promising therapeutic avenue for HCC.
  • Further research and clinical trials are warranted to evaluate the efficacy of MET inhibitors in HCC patients.
Keywords:
HGFMETbiomarkersclinical trialshepatocellular carcinoma

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.3K
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

2.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
291
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
333
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K